ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 165

Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study

Daria B. Crittenden1, Cilian J. White1, Michael DeBerardine1, Grace Kim2, Binita Shah3, Jessica C. Kimmel1, Rima D. Patel1, Steven P. Sedlis3, Jeffrey D. Greenberg4, Craig T. Tenner5, Bruce N. Cronstein1 and Michael H. Pillinger1, 1Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, 2NYU School of Medicine, Division of Rheumatology, New York, NY, 3NYU School of Medicine, Division of Cardiology, New York, NY, 4Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 5Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, colchicine and gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Atherosclerosis is an inflammatory process, but to date no anti-inflammatory agent has definitively been shown to alter cardiovascular (CV) risk. Colchicine is an anti-inflammatory agent that inhibits macrophages, endothelial cells, and neutrophils, all implicated in atherosclerosis. In a cross-sectional study, we found that colchicine use was associated with reduced prevalence of myocardial infarction (MI) in gout patients [1]. To further evaluate the relationship between colchicine and CV risk, we initiated a retrospective cohort study. Here we present an interim analysis.

Methods: We identified all active New York Harbor VA patients with an assigned ICD-9 code for gout or hyperuricemia between 2000-09. Charts were manually screened to confirm a diagnosis of gout utilizing ACR criteria, and pharmacy records were used to identify subjects on daily colchicine for ≥ 30 days (colchicine group). Subjects receiving no colchicine prescriptions formed the control group. Baseline characteristics including CV risk factors and medication use were ascertained. We excluded patients who did not meet our diagnostic criteria for gout, who received as-needed colchicine only, or with ≤ 3 months of follow-up time available for evaluation. We defined colchicine lapse as any period of non-colchicine use beginning 2 weeks after medication cessation (to account for the elimination time of the drug). The primary outcome was MI during the study period.  

Results: 7819 subjects had requisite ICD-9 codes. Among 1031 charts reviewed to date, 214 patients met gout criteria and 183 were enrolled. Of these, 121 subjects (66%) used colchicine (totaling 363.8 patient-years of exposure) and 62 subjects (34%) used no colchicine (totaling 249.8 patient-years of follow-up). Colchicine and control groups had similar rates of hypertension (0.85 vs 0.92, p=0.2), diabetes (0.37 vs 0.3, p=0.4), hyperlipidemia (0.66 vs 0.56, p=0.3), coronary artery disease (0.29 vs 0.37, p= 0.3), and allopurinol use (0.22 vs 0.21, p= 1.0), as well as similar BMI (30.6 vs 29.8, p=0.3), serum urate (8.4 vs 8.2 mg/dL, p=0.6), and creatinine (1.3 vs 1.4 mg/dL, p=0.7). Colchicine users experienced no MIs while on their medication. In contrast, control patients had 4 MIs (0 vs 6.4%; p=0.01), and 3 MIs occurred during colchicine lapses (3%; lapse vs colchicine p=0.09; lapse vs control p=0.43; mean time from last colchicine use to MI 5.9 months). We also compared rates of MI per patient-year between colchicine exposure (0.0), control follow-up (0.016), and colchicine lapse follow-up (0.018) periods, and observed significant differences between colchicine vs control (p=0.036) and colchicine vs lapse (p=0.035), but not between control vs lapse group MI rates (p=0.26). 

Conclusion: In this interim analysis, gout patients taking colchicine had a significantly reduced rate of MI vs non-users, and vs themselves during periods when not taking colchicine. These data suggest that colchicine is protective against MI, though probably only during active use. Evaluation of the remaining 6,788 patients is ongoing.

[1] Crittenden DB et al. J Rheum 2012 E Pub.


Disclosure:

D. B. Crittenden,
None;

C. J. White,
None;

M. DeBerardine,
None;

G. Kim,
None;

B. Shah,
None;

J. C. Kimmel,
None;

R. D. Patel,
None;

S. P. Sedlis,
None;

J. D. Greenberg,
None;

C. T. Tenner,
None;

B. N. Cronstein,

Canfite BioPharma,

1,

NIH, URL Pharma, OSI,

2,

Bristol-Myers Squibb, Novartis, URL, Regeneron, Gismo Therapeutics,

5,

Arthritis Foundation, SLE Foundation,

6,

Patents on use of adenosine receptor antagonists to treat or prevent fibrosis. Multiple other patents.,

;

M. H. Pillinger,

Takeda Inc,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/colchicine-is-associated-with-a-decreased-rate-of-myocardial-infarction-in-gout-patients-interim-results-from-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology